Eli Lilly and Company has announced the opening of the Lilly Seaport Innovation Center (LSC) in Boston's Seaport district, a state-of-the-art facility dedicated to advancing RNA and DNA-based therapies and discovering new drug targets. The 346,000-square-foot, 12-story building, developed by Alexandria Real Estate Equities, Inc., will house around 500 Lilly scientists and researchers, alongside 200 professionals from partner companies within Lilly Gateway Labs. The LSC will focus on addressing major disease areas such as diabetes, obesity, cardiovascular conditions, neurodegeneration, and chronic pain, fostering a collaborative environment to accelerate the development of transformative medicines.
Daniel Skovronsky, Chief Scientific Officer at Lilly, emphasized the company's commitment to innovation and collaboration in Boston's vibrant research community. Lilly Gateway Labs, an integral part of the new center, connects early-stage biotech companies with Lilly's extensive expertise and resources, supporting the advancement of novel therapeutics. Since its inception in San Francisco in 2019, Gateway Labs has supported over 20 biotechs and facilitated the development of numerous therapeutics, underscoring Lilly's dedication to addressing global health challenges through groundbreaking scientific research.
